A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy-Reference-Cited by-同舟云学术

A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy

Published:2020-05 Issue:5 Volume:15 Page:e69-e72
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Liu Zhichao,Xie Zhanhong,Cai Xiuyu,He Jianxing,Liang Wenhua^ORCID

Funder

National Science Foundation

Key Project of Guangzhou Scientific Research Project

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. Wang Z, Duan J, Wang G, et al. Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors [e-pub ahead of print]. J Thorac Oncol. https://doi.org/10.1016/j.jtho.2019.12.001, accessed December 13, 2019.

2. Identification of neutral tumor evolution across cancer types;Williams;Nat Genet,2016

3. Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC;Liu;Translational Lung Cancer Research,2019

4. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab;Gandara;Nat Med,2018

5. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER Database and a Chinese multi-institutional registry;Liang;J Clin Oncol,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advance of next-generation sequencing in patients with lung cancer;Expert Review of Molecular Diagnostics;2023-09-26

2. Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives;Cell Death & Disease;2023-03-31

3. Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer;Cancers;2022-11-17

4. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms;Frontiers in Immunology;2022-09-27

5. Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC;Cancers;2022-05-26